AU2017237929B2 - Pyrimidines and variants thereof, and uses therefor - Google Patents

Pyrimidines and variants thereof, and uses therefor Download PDF

Info

Publication number
AU2017237929B2
AU2017237929B2 AU2017237929A AU2017237929A AU2017237929B2 AU 2017237929 B2 AU2017237929 B2 AU 2017237929B2 AU 2017237929 A AU2017237929 A AU 2017237929A AU 2017237929 A AU2017237929 A AU 2017237929A AU 2017237929 B2 AU2017237929 B2 AU 2017237929B2
Authority
AU
Australia
Prior art keywords
compound
mmol
mixture
formula
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017237929A
Other languages
English (en)
Other versions
AU2017237929A1 (en
Inventor
Anthony P. FORD
Joel R. Gever
Ronald Charles Hawley
Prabha Ibrahim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Afferent Pharmaceuticals Inc
Original Assignee
Afferent Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afferent Pharmaceuticals Inc filed Critical Afferent Pharmaceuticals Inc
Publication of AU2017237929A1 publication Critical patent/AU2017237929A1/en
Application granted granted Critical
Publication of AU2017237929B2 publication Critical patent/AU2017237929B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2017237929A 2016-03-25 2017-03-20 Pyrimidines and variants thereof, and uses therefor Active AU2017237929B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662313334P 2016-03-25 2016-03-25
US62/313,334 2016-03-25
PCT/US2017/023126 WO2017165255A1 (en) 2016-03-25 2017-03-20 Pyrimidines and variants thereof, and uses therefor

Publications (2)

Publication Number Publication Date
AU2017237929A1 AU2017237929A1 (en) 2018-09-13
AU2017237929B2 true AU2017237929B2 (en) 2021-04-15

Family

ID=59900805

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017237929A Active AU2017237929B2 (en) 2016-03-25 2017-03-20 Pyrimidines and variants thereof, and uses therefor

Country Status (11)

Country Link
US (2) US10662162B2 (enExample)
EP (1) EP3433258B1 (enExample)
JP (1) JP6902045B2 (enExample)
KR (1) KR102377805B1 (enExample)
CN (1) CN108779119B (enExample)
AU (1) AU2017237929B2 (enExample)
CA (1) CA3018180C (enExample)
MA (1) MA44489A (enExample)
MX (1) MX384368B (enExample)
RU (1) RU2760733C2 (enExample)
WO (1) WO2017165255A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10822311B2 (en) 2016-03-14 2020-11-03 Afferent Pharmaceuticals, Inc. Pyrimidines and variants thereof, and uses therefor
WO2017165255A1 (en) * 2016-03-25 2017-09-28 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
WO2018116139A1 (en) 2016-12-19 2018-06-28 Novartis Ag New picolinic acid derivatives and their use as intermediates
JP6934945B2 (ja) * 2016-12-20 2021-09-15 アファレント ファーマシューティカルズ インコーポレイテッド Ｐ２ｘ３アンタゴニストの結晶塩および多形
CA3076680A1 (en) * 2017-11-01 2019-05-09 Beijing Tide Pharmaceutical Co., Ltd. P2x3 and/or p2x2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof
CN107778255B (zh) * 2017-11-16 2019-10-25 山东大学 一种二芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用
CN114007620B (zh) * 2019-04-30 2024-08-06 北京泰德制药股份有限公司 二氨基嘧啶类化合物治疗子宫内膜异位相关的疼痛的方法
MX2021013338A (es) * 2019-04-30 2022-01-24 Beijing Tide Pharmaceutical Co Ltd Método para tratar la tos usando un compuesto de diaminopirimidina.
SG11202111907UA (en) * 2019-04-30 2021-11-29 Beijing Tide Pharmaceutical Co Ltd Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof
EP3981765A4 (en) * 2019-06-06 2023-05-31 Beijing Tide Pharmaceutical Co., Ltd. P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION CONTAINING IT AND THEIR USE
CN120058573A (zh) * 2025-04-29 2025-05-30 潍坊学院 一种1-三溴甲基磺酰基萘及其衍生物的合成方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059893A1 (en) * 1999-04-06 2000-10-12 Krenitsky Pharmaceuticals Inc. Neurotrophic thio substituted pyrimidines
WO2005095359A1 (en) * 2004-03-05 2005-10-13 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 antagonists
WO2007025900A1 (en) * 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p3x2/3 modulators
WO2007025899A1 (en) * 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
WO2007025925A1 (en) * 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
WO2007025901A1 (en) * 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
WO2017160569A1 (en) * 2016-03-14 2017-09-21 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2953567A (en) * 1956-11-23 1960-09-20 Burroughs Wellcome Co 5-phenylmercaptopyrimidines and method
CA2432799C (en) * 2000-12-21 2008-08-19 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
SI2343281T1 (sl) * 2006-10-04 2014-06-30 F. Hoffmann-La Roche Ag Postopek za sintezo fenoksi diaminopirimidinskih derivatov
WO2008104472A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag 2, 4 -diaminopyrimidine derivatives and their use as p2x antagonists or as prodrugs thereof
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
CN101842359A (zh) * 2007-10-31 2010-09-22 日产化学工业株式会社 哒嗪酮化合物和p2x7受体抑制剂
GB2471713A (en) 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
TWI637949B (zh) * 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
MX367657B (es) * 2013-08-23 2019-08-30 Afferent Pharmaceuticals Inc Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica.
US10195198B2 (en) * 2014-07-03 2019-02-05 Afferent Pharmaceuticals, Inc. Methods and compositions for treating diseases and conditions
WO2017165255A1 (en) 2016-03-25 2017-09-28 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059893A1 (en) * 1999-04-06 2000-10-12 Krenitsky Pharmaceuticals Inc. Neurotrophic thio substituted pyrimidines
WO2005095359A1 (en) * 2004-03-05 2005-10-13 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 antagonists
WO2007025900A1 (en) * 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p3x2/3 modulators
WO2007025899A1 (en) * 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
WO2007025925A1 (en) * 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
WO2007025901A1 (en) * 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
WO2017160569A1 (en) * 2016-03-14 2017-09-21 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bredereck von H. et al., Acid amide reaction. XXXV. Mechanism of the new purine synthesis; Justus Liebigs Annalen der Chemie, 1964, 673, 88-92. *
Falco, E. A. et al., 5-Arylthiopyrimidines. I. 2, 4-Diamino derivatives; Journal of Organic Chemistry, 1961, 26, 1143-6. *
Zhao, Weizhang et al., Synthesis and antibacterial activity of 2, 4-diamino-5-(substituted aniline)pyrimidines; Yaoxue Xuebao 1987, 22(7), 541-4. *

Also Published As

Publication number Publication date
KR20180128015A (ko) 2018-11-30
WO2017165255A1 (en) 2017-09-28
CN108779119A (zh) 2018-11-09
RU2760733C2 (ru) 2021-11-30
MX2018011622A (es) 2019-03-28
US10662162B2 (en) 2020-05-26
JP6902045B2 (ja) 2021-07-14
MA44489A (fr) 2019-01-30
EP3433258A1 (en) 2019-01-30
MX384368B (es) 2025-03-14
RU2018137032A (ru) 2020-04-27
CA3018180C (en) 2024-02-20
JP2019510025A (ja) 2019-04-11
US11230532B2 (en) 2022-01-25
US20200239421A1 (en) 2020-07-30
RU2018137032A3 (enExample) 2020-05-22
KR102377805B1 (ko) 2022-03-22
CN108779119B (zh) 2022-02-08
EP3433258A4 (en) 2019-10-30
EP3433258B1 (en) 2023-07-19
BR112018069105A2 (pt) 2019-01-29
AU2017237929A1 (en) 2018-09-13
US20190055202A1 (en) 2019-02-21
CA3018180A1 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
AU2017237929B2 (en) Pyrimidines and variants thereof, and uses therefor
AU2017233841B2 (en) Pyrimidines and variants thereof, and uses therefor
CN111377917B (zh) 杂环类化合物、中间体、其制备方法及应用
CN104768932B (zh) Pde4的杂芳基抑制剂
CN113173924B (zh) 一种作为cdk抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途
CN107793413A (zh) 嘧啶杂环化合物及其制备方法和应用
KR20150128722A (ko) 카텝신 c의 억제제로서 치환된 2-아자-바이사이클로[2.2.1]헵탄-3-카복실산(벤질-시아노-메틸)-아미드
AU2010332969A1 (en) New CCR2 receptor antagonists and uses thereof
JP2012519678A (ja) キナーゼ阻害剤として使用されるピロロピリミジン
WO2016169421A1 (zh) 咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用
EP3247705B1 (en) Quinazoline and quinoline compounds and uses thereof as nampt inhibitors
WO2022166974A1 (zh) 吡啶并嘧啶酮类衍生物及其制备方法和用途
TW202017916A (zh) 新穎緩激肽ｂ２受體拮抗劑及其用途
JP2018531993A (ja) Ａｌｋおよびｓｒｐｋ阻害剤ならびに使用方法
CN113490668A (zh) 用于治疗与apj受体活性有关的疾病的化合物和组合物
JP2025517511A (ja) Ｔｒｐｍ３媒介性障害を治療するための新たな誘導体
BR112018069105B1 (pt) Composto de pirimidina, composição e uso do mesmo
JP2006513218A (ja) インテグリン受容体アンタゴニスト誘導体としてのピラゾール化合物
JP2025517513A (ja) Ｔｒｐｍ３媒介性障害を治療するための新たな誘導体
HK40048952A (en) Heterocyclic compound, intermediate, preparation method therefor and application thereof
HK40061670A (en) Compounds and compositions for treating conditions associated with apj receptor activity
WO2020119590A1 (zh) 3-氰基吡啶类化合物、包含其的药物组合物及其制备方法和用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)